<DOC>
	<DOCNO>NCT00076206</DOCNO>
	<brief_summary>The primary objective study compare therapeutic response safety 3 oral dose level CCI-779 , placebo subject active rheumatoid arthritis ( RA ) receive stable dos methotrexate ( MTX ) least 8 week .</brief_summary>
	<brief_title>Study Evaluating CCI-779 Active Rheumatoid Arthritis Concomitant Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Meet American College Rheumatology ( ACR ) criteria RA Have active RA consist ≥ 6 swollen ≥ 6 painful joint ACR functional class IIII Exclusion Criteria At screen subject 's prior medication review . ( Prior history diseasemodifying antirheumatic drug ( DMARD ) use record , include start stop date recently take DMARDs ) Significant concurrent medical disease Abnormal chest radiograph , include finding consistent interstitial pneumonitis , granulomatous disease , pleural effusion and/or infiltration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>